HAGAR

Executive Summary

HAGAR is an Israeli medtech startup developing GWave, the first non-invasive continuous glucose monitoring (CGM) system using low-power radio-frequency waves and AI algorithms. The device, which connects via Bluetooth to a smartphone app and cloud platform, aims to provide painless, real-time blood glucose monitoring for diabetes patients. Founded in 2020 and based in Tel Aviv, the company has raised $21.1 million and is currently in Phase 2 development. GWave's technology could disrupt the CGM market dominated by invasive sensors, potentially improving patient compliance and outcomes. If successful, HAGAR addresses a significant unmet need for a non-invasive alternative, with a target market of millions of diabetes patients worldwide. However, technical challenges and regulatory hurdles remain, and the company must demonstrate accuracy equivalent to existing CGMs in larger trials.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 clinical trial results60% success
• Q2 2027FDA pre-submission or breakthrough device designation40% success
• TBDStrategic partnership with a diabetes care company50% success